9.74
+0.68(+7.51%)
Currency In USD
| Previous Close | 9.06 |
| Open | 8.92 |
| Day High | 9.91 |
| Day Low | 8.85 |
| 52-Week High | 28.25 |
| 52-Week Low | 5.9 |
| Volume | 5.88M |
| Average Volume | 8.14M |
| Market Cap | 1.02B |
| PE | -2.29 |
| EPS | -4.25 |
| Moving Average 50 Days | 15.79 |
| Moving Average 200 Days | 11.42 |
| Change | 0.68 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $440.72 as of December 05, 2025 at a share price of $9.74. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $209.06 as of December 05, 2025 at a share price of $9.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
GlobeNewswire Inc.
Nov 10, 2025 8:17 PM GMT
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 2
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
GlobeNewswire Inc.
Nov 08, 2025 10:13 PM GMT
Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for at least se
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
GlobeNewswire Inc.
Oct 27, 2025 11:30 AM GMT
Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today